{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":2,"podcast":2,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT03738228","nct_id":"NCT03738228","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03738228. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive atezolizumab IV over 30-60 minutes on days -21, 0, and 21 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy IV over 90 minutes on days 0, 7, 14, 21, 28, and 35. Beginning on day 0, patients also receive standard of care radiation therapy once daily (Monday-Friday) for a total of 25 fractions with image guided brachytherapy beginning in week 4, 5, or at the end of radiation therapy.","label":"Arm A (atezolizumab, standard cisplatin and radiation therapy)","type":"EXPERIMENTAL"},{"description":"Patients receive atezolizumab IV over 30-60 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy, radiation therapy, and image guided brachytherapy as in Arm A.","label":"Arm B (atezolizumab, standard cisplatin and radiation therapy)","type":"EXPERIMENTAL"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2025-09-12","type":"ACTUAL"},"conditions":["Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma","Stage IB2 Cervical Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IVA Cervical Cancer AJCC v8"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Brachytherapy","type":"RADIATION"},{"name":"Cisplatin","type":"DRUG"},{"name":"Radiation Therapy","type":"RADIATION"}],"last_update":"2025-11-12","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2022-05-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Immune Response","timeFrame":"Arm A: 42 days from the first dose of Atezolizumab Arm B: 21 days from the first dose of Atezolizumab"}],"references":[{"citation":"Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int J Gynecol Cancer. 2020 May;30(5):701-704. doi: 10.1136/ijgc-2019-001012. Epub 2019 Dec 22.","pmid":"31871115","type":"DERIVED"}],"start_date":{"date":"2019-01-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer","url":"https://clinicaltrials.gov/study/NCT03738228"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03738228"}